Top broker names 3 healthcare shares to buy Viralytics Ltd....

Top broker names 3 healthcare shares to buy


Viralytics Ltd. (ASX: VLA)
Finally, this exciting biotech company has been given a speculative buy rating and a $2.33 price target. The broker appears to have been impressed with Viralytics’ clinical trial results for its treatment for patients whose cancer has relapsed following treatment with first line therapies. I’ve written a few times in the past about Viralytics being one to watch and I still feel it is the case today. However, there is still a long road ahead for the company, so I’m not a buyer just yet. But I intend to keep a close eye on it and would suggest investors do the same.

http://www.********.au/2017/07/10/top-broker-names-3-healthcare-shares-to-buy/